RxDoctor Payments Data

Ahmad Alqaqa, MD

Interventional Cardiology · Lakewood, CONPI 1962660423

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $9,204 of the $14,990 with a category attached, or 61.4%. 39 manufacturers reported payments, led by Medtronic at 33.8% of the total.

$14,990in general payments, 2019–2025

Across 318 payments — averaging $47.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$2K
  • Edwards Lifesciences$1K
  • CMS Imaging, Inc.$1K
  • Amgen$1K
  • Abbott$454
  • plus $4K from 33 others

What the payments were for

  • Travel & lodging$5,34536%
  • Food & beverage$9,20461%
  • Education$2161%
  • Other$2241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,990 in reported general payments places this provider in the 60th percentile of 111 interventional cardiology providers in Colorado.

See all interventional cardiology providers in Colorado

Medicare billing

Part B allowed, 2024
$224,700
Medicare patients
1,449
Services billed
3,149

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban308$346,772
Repatha SureclickEvolocumab130$104,748
EntrestoSacubitril/Valsartan37$48,609
JardianceEmpagliflozin27$31,984
XareltoRivaroxaban18$23,784
FarxigaDapagliflozin Propanediol19$21,408
Metoprolol Succinate400$3,771
ClopidogrelClopidogrel Bisulfate300$3,199
Atorvastatin Calcium357$2,877
Ezetimibe100$2,394
Rosuvastatin Calcium178$2,282
Prasugrel Hcl21$1,566
Flecainide Acetate25$1,144
Losartan Potassium128$931
Torsemide28$847

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$298$346,772308 claims
NovartisEntresto$147$48,60937 claims
Boehringer IngelheimJardiance$73$31,98427 claims
Johnson & JohnsonXarelto$383$23,78418 claims
AstraZenecaFarxiga$102$21,40819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 111 interventional cardiology providers in Colorado.

Other interventional cardiology in Lakewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →